Retatrutide is making headlines, and if you heard the recent reports of average weight loss approaching 30% in a major clinical trial, I understand why the medication is getting attention. Those results are significant. But as a nurse practitioner who works in the weight-management and wellness space, I think the more important conversation begins after the headline.

What exactly is retatrutide? How is it different from the medications already being used for obesity? Does nearly 30% weight loss mean that’s what everyone can expect? What do we know about side effects? And perhaps most importantly right now: Can you actually get retatrutide?

As of October 2026, retatrutide remains an investigational medication. It is not FDA approved. That doesn’t mean the FDA reviewed it and rejected it. Eli Lilly is still completing the process required before regulatory review and has said it plans to submit retatrutide for U.S. approval in the first quarter of 2027. That’s an important distinction as excitement about this medication grows.

What Is Retatrutide?

Retatrutide is a once-weekly injectable medication being developed for obesity and related metabolic conditions. To understand why it’s being called a “triple agonist,” it helps to look at the medications that came before it.

Semaglutide acts primarily at the GLP-1 receptor. Tirzepatide targets both GLP-1 and GIP receptors. Retatrutide acts at three: GLP-1, GIP and glucagon receptors. GLP-1 and GIP are involved in appetite, glucose regulation and other metabolic processes. Glucagon is often introduced to people simply as the hormone that raises blood glucose, but its physiology is more complicated than that. Glucagon signaling also affects energy metabolism.

Researchers are investigating whether combining activity at all three receptors in one molecule can produce additional metabolic and weight-related effects. So, although you’ll frequently see retatrutide grouped under the broad “GLP-1” umbrella, it isn’t simply another version of semaglutide.

Why Is Everyone Talking About Nearly 30% Weight Loss?

The newest attention comes from the Phase 3 TRIUMPH-1 trial, published in The New England Journal of Medicine in September 2026. Researchers studied adults with obesity who did not have diabetes and randomly assigned participants to receive placebo or one of several doses of retatrutide for 80 weeks. At the highest 12-mg dose, participants lost an average 28.3% of their starting body weight using the trial’s efficacy estimand. Now that deserves attention, but it also deserves context.

An average from a clinical trial is not a prediction of what will happen to an individual woman. Some participants lose more, some lose less, and some discontinue treatment. Trial populations and study conditions also don’t perfectly reproduce everyday clinical practice. There is another important reason not to turn “28.3%” into the number everyone should expect.

In the separate TRIUMPH-2 Phase 3 trial involving adults with overweight or obesity and type 2 diabetes, participants receiving the highest dose lost an average 20.8% at 80 weeks according to Lilly’s reported topline results. Still substantial but not 28.3%. Different populations can respond differently.

That’s one reason I would also be cautious about headlines suggesting that retatrutide has already been proven “better” than semaglutide or tirzepatide. Results from separate trials can be interesting to compare, but they are not equivalent to a randomized head-to-head trial designed specifically to determine superiority.

What Do We Know About Retatrutide Side Effects?

The gastrointestinal effects will sound familiar to anyone who follows GLP-1-based obesity treatment. Nausea, diarrhea, constipation and vomiting were among the most commonly reported adverse effects in Phase 3 research, with gastrointestinal symptoms occurring more frequently at higher doses. But another side effect has attracted attention because it isn’t something most people immediately associate with weight-loss medication: dysesthesia, or altered skin sensation.

Earlier Phase 2 research reported hyperesthesia and related changes in skin sensitivity in some participants. In the Phase 3 TRIUMPH-1 safety data, dysesthesia was reported in approximately 5% of participants receiving 4 mg, 12% receiving 9 mg and 13% receiving 12 mg, compared with 1% receiving placebo. Reported events were generally mild to moderate, and most resolved during treatment. That doesn’t mean everyone who eventually takes retatrutide will experience altered skin sensations. It means it’s part of the emerging safety information researchers and regulators will consider.

And that’s precisely why Phase 3 trials and regulatory review matter. Weight-loss percentages make headlines. Safety data matter just as much.

Retatrutide Is Not FDA Approved Yet

This is probably the most important section of this article. Lilly has announced positive Phase 3 results and says it now has clinical data supporting planned regulatory submissions. However, the company has stated that it plans to submit retatrutide for U.S. approval in the first quarter of 2027. In other words, as of this writing, the planned FDA application has not yet been submitted.

After submission, FDA must evaluate the evidence before deciding whether the medication should be approved and under what indications and labeling. So, when television reports describe exciting retatrutide results, they are reporting clinical research and not the arrival of a newly approved medication at your pharmacy.

What About “Compounded Retatrutide” Being Sold Online?

This is where I want women to be particularly careful. You may already find websites, wellness businesses or social media accounts advertising products described as retatrutide. That does not mean you’re purchasing the investigational product used in Lilly’s clinical trials.

FDA currently states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot currently be used in compounding under federal law. The agency has already taken enforcement action involving companies marketing unapproved retatrutide products.

So, if someone tells you she is already taking “retatrutide,” that should not be interpreted as evidence that the medication described in these Phase 3 trials is commercially available. It isn’t. And promising research results should never become a reason to purchase an investigational peptide from an unverified source.

What Does This Mean for Women Over 40?

Here’s where I think the conversation becomes particularly important for the women I serve. When medications become capable of producing increasingly substantial weight loss, we cannot allow the percentage of body weight lost to become our only definition of success. Women in midlife are already navigating age-related changes in muscle, bone, body composition and metabolic health. Menopause can add another layer. If a woman loses 20%, 25% or potentially more of her body weight, I don’t only want to know what the scale says. I want to know: What is she losing, and what is she preserving?

Intentional weight loss can include loss of lean tissue along with fat. That doesn’t make weight loss inherently harmful, nor does it mean GLP-1-based medications uniquely “eat muscle,” as some social-media headlines suggest. But preserving skeletal muscle through appropriate nutrition and resistance exercise becomes increasingly important when significant weight loss is occurring. For a woman over 40, the goal shouldn’t simply be the lowest number a medication can produce.

We should also be thinking about strength, function, nutrition, bone health, cardiometabolic health and the ability to maintain healthy behaviors over time. That’s one of the reasons I continue to emphasize lifestyle support even as obesity medications become more effective. Medication and lifestyle care are not competitors. They address different pieces of the same health journey.

What Don’t We Know Yet?

This is the part of “new” drug conversations that often gets lost in excitement. We still need the full regulatory review. We need continued safety monitoring. We need more information about long-term real-world use. We need to understand how treatment will eventually be positioned relative to existing obesity medications if approval occurs.

We also don’t know what retatrutide would cost. Because there is no FDA-approved commercial retatrutide product yet, there is currently no established U.S. retail price, insurance coverage landscape or standard patient out-of-pocket cost to report.

Those questions will matter tremendously if the medication reaches the market. But right now, attaching a predicted price to retatrutide would be speculation.

My Takeaway as a Nurse Practitioner

I think retatrutide is worth watching. A Phase 3 trial demonstrating average weight loss of this magnitude is clinically important, and obesity medicine continues to change rapidly. But enthusiasm and caution can exist at the same time.

We can recognize promising science without turning preliminary availability into reality. We can discuss impressive weight loss without promising every woman the same result. And we can welcome more effective obesity treatments while still remembering that health after 40 is about much more than becoming smaller.

If retatrutide eventually receives FDA approval, we’ll have another conversation about where it may fit. But for now, remember three things:

• The research is promising.
• Retatrutide is still investigational.
• And anything being sold to you as retatrutide today is not an FDA-approved retatrutide medication.

Sometimes good health information isn’t about being first to try the newest thing. Sometimes it’s about knowing enough to wait for the evidence.

Continue Your Wellness Journey

At Ample Health & Wellness, I help women over 40 look beyond quick fixes and build sustainable habits around nutrition, movement, metabolic health, menopause, sleep, stress and weight management. If you’re currently using a GLP-1-based medication or working on weight loss after 40, explore more of our evidence-informed resources on GLP-1 lifestyle support, muscle preservation and sustainable weight management. You can also join Wellness Weekly for practical, evidence-informed conversations designed for women navigating health and weight after 40.

References

1. Jastreboff, A. M., et al. (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity. The New England Journal of Medicine. NEJM TRIUMPH-1 study
2. Jastreboff, A. M., et al. (2023). Triple–hormone-receptor agonist retatrutide for obesity—A phase 2 trial. The New England Journal of Medicine, 389, 514–526. NEJM Phase 2 study
3. U.S. Food and Drug Administration. (2026). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. FDA guidance and warning
4. Eli Lilly and Company. (2026). Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. Lilly TRIUMPH-2 and TRIUMPH-3 results

About the Author

Dr. Kisha Pickford, DNP, ACNP-BC is a board-certified nurse practitioner, holistic nutrition weight loss coach and GLP-1 lifestyle integration coach. Through Ample Health & Wellness, she helps women over 40 build sustainable, evidence-informed habits that support weight management, metabolic wellness and whole-person health.

Medical Disclaimer

This article is for educational and informational purposes only and does not provide individualized medical advice, diagnosis or treatment. Retatrutide remains investigational and is not currently FDA approved. Questions about obesity treatment or prescription medication should be discussed with an appropriately licensed healthcare professional.